Clinical outcomes following heart transplantation

Mount Sinai Journal of Medicine

Volumn 79, Issue 3, 2012, Pages 317-329

  Murphy, Laura ^a   Pinney, Sean P ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Calcineurin inhibitors; Cardiac allograft vasculopathy; Endomyocardial biopsy; Heart transplant

Indexed keywords

ANTIMETABOLITE; AZATHIOPRINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; AVASCULAR NECROSIS; CANCER SUSCEPTIBILITY; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CATARACT; CHRONIC KIDNEY DISEASE; COLON PERFORATION; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DIGESTIVE SYSTEM ULCER; DRUG SAFETY; DYSLIPIDEMIA; EDEMA; HEADACHE; HEART FAILURE; HEART RIGHT VENTRICLE FAILURE; HEART TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; INSULIN RESISTANCE; LEUKOCYTE COUNT; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL FUNCTION; NEOPLASM; NEUROLOGICAL COMPLICATION; OSTEOPOROSIS; PERICARDIAL EFFUSION; PNEUMONIA; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; PROTEINURIA; PSYCHOSIS; QUALITY OF LIFE; RETRANSPLANTATION; REVIEW; SEIZURE; SIDE EFFECT; SURVIVAL; TREATMENT OUTCOME; TREMOR; UNSPECIFIED SIDE EFFECT; VASOPLEGIA; WOUND HEALING IMPAIRMENT;

BIOPSY; CALCINEURIN; ENDOCARDIUM; HEART FAILURE; HEART TRANSPLANTATION; HEMODYNAMICS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOCARDIUM; TRANSPLANTATION TOLERANCE; TREATMENT OUTCOME;

EID: 84862176237     PISSN: 00272507     EISSN: 19317581     Source Type: Journal    
DOI: 10.1002/msj.21311     Document Type: Review

References (20)

1. Stehlik J, Edwards LB, Kucheryavaya AY, et al. The registry of the International Society for Heart and Lung Transplantation: Twenty-eighth Adult Heart Transplant Report-2011. J Heart Lung Transplant 2011; 30: 1078-1094.
2. Weiss ES, Allen JG, Kilic A, et al. Development of a quantitative donor risk index to predict short-term mortality in orthotopic heart transplantation. J Heart Lung Transplant 2012; 31: 266-273.
3. Chan MC, Kwok BW, Shiba N, et al. Conversion of cyclosporine to tacrolimus for refractory or persistent myocardial rejection. Transplant Proc 2002; 34: 1850-1852.
4. Pinney SP, Balakrishnan R, Dikman S, et al. Histopathology of renal failure after heart transplantation: a diverse spectrum. J Heart Lung Transplant 2012; 31: 233-237.
5. Eisen H, Kobashigawa J, Keogh A, et al. Three year results of a randomized, double blind controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005; 24: 517-525. (Pubitemid 40693872)
6. Mancini DM, Pinney SP, Burkoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48-53.
7. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858. (Pubitemid 37025404)
8. Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: Twenty-second Official Adult Heart Transplant Report-2005. J Heart Lung Transplant 2005; 24: 945-955. (Pubitemid 41127174)
9. Byrne JG, Leacche M, Paul S, et al. Risk factors and outcomes for 'vasoplegia syndrome' following cardiac transplantation. Eur J Cardiothorac Surg 2004; 25: 327-332. (Pubitemid 38340565)
10. Edwards RM, Trizna W, Kinter LB. Renal microvascular effects of vasopressin and vasopressin antagonist. Am J Physiol 1989; 256(2 part 2): F274-F278.
11. Kubo SH, Naftel DC, Mills RM Jr, et al. Risk factors for late recurrent rejection after heart transplantation: a multi-institutional, multi-variable analysis. J Heart Lung Transplant 1995; 14: 409-418.
12. Kirklin JK, Young JB, McGiffin DC, eds. Heart Transplantation. Philadelphia, PA: Churchill Livingstone; 2002.
13. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005; 24: 1710-1720. (Pubitemid 41641841)
14. Reed EF, Demetris AJ, Hammond E, et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006; 25: 153-159. (Pubitemid 43156365)
15. Francis GS, Greenberg BH, Hsu DT, et al. ACCF/AHA/ACP/HFSA/ISHLT 2010 clinical competence statement on management of patients with advanced heart failure and cardiac transplant: a report of the ACCF/AHA/ACP Task Force on Clinical Competence and Training. J Am Coll Cardiol 2010; 56: 424-453.
16. Miller LW, Naftel DC, Bourge RC, et al. Infection after heart transplantation: a multi-institutional study. J Heart Lung Transplant 1994; 13: 381-393. (Pubitemid 24168322)
17. Costanzo M, Naftel D, Pritzker M, et al. Heart transplant coronary artery disease detected by coronary angiography: a multi-institutional study of preoperative donor and recipient risk factors. J Heart Lung Transplant 1998; 17: 744-753. (Pubitemid 28396983)
18. Mehra MR, Crespo-Leiro MG, Dipchand A, et al. International Society for Heart and Lung Transplantation working formulation of a standardized nomenclature for cardiac allograft vasculopathy-2010 [published correction appears in J Heart Lung Transplant 2011;30:360]. J Heart Lung Transplant 2010; 29: 717-727.
19. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995; 333: 621-627.
20. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940. (Pubitemid 37064766)